Ludwig Enterprises Files Patent for Messenger Ribonucleic Acid (mRNA) – Ludwig mRNA Inflammatory Index™
SPARKS, NV / ACCESSWIRE / Sep 22, 2022 / (OTC PINK: LUDG) Ludwig Enterprises, a leading innovator of genetic inflammatory biomarkers for diagnosing and monitoring chronic diseases, is pleased to announce that the company has filed a patent on proprietary technology, the “Ludwig mRNA Inflammatory Index™”. The patent covers the application of messenger ribonucleic acid (mRNA) in the diagnosis, management and evaluation of the response to treatment of patients with inflammatory diseases in heart disease, diabetes, autoimmune diseases, preeclampsia and bladder, colon and breast cancer.
“The cutting-edge technology described in this patent has the potential to help people live longer, healthier lives,” said Dr. Marvin S. Hausman, Chairman of the Ludwig Scientific Advisory Board (SAB). “The patent covers the company’s proprietary test methods that can measure genetic inflammatory biomarkers for diseases such as heart disease, preeclampsia or cancer. These diseases are often silent and asymptomatic before rearing their ‘ugly head’. Ludwig’s technology has the potential to predict disease development and allow clinicians to monitor a patient’s response and modify treatment steps as needed.”
The mRNA molecule carries the genetic information necessary for cells to make proteins. Because the data in DNA cannot be directly decoded into proteins, it is first transcribed or copied into mRNA. Each mRNA molecule encodes the information for a protein. The mRNA molecules are transported through the outer envelope of a cell into the cytoplasm, where they are translated by rRNA in ribosomes, cellular structures that carry out biological protein synthesis. The specific amounts of amino acids in a protein and their sequence determine the unique properties of the protein; For example, muscle protein and hair protein contain the same 20 amino acids, but the sequences of these amino acids in the two proteins are quite different. The mRNA segments are like a written message, and these “words” are translated into specific amino acids that make up the protein. One example is mRNA vaccines that teach our cells how to make a protein that will trigger an immune response within our body. Like all vaccines, mRNA vaccines benefit those who are vaccinated by protecting them against diseases like COVID-19 without risking the potentially serious consequences of getting sick.
The Ludwig mRNA Inflammatory Index™ will be used in the recent announcement: “Ludwig Enterprises and Emerson Urology Associates plan study of BCG immunotherapy for bladder cancer.
Clinically, high-risk non-muscle invasive bladder cancer (NMIBC) is treated with adjuvant intravesical instillations of bacillus Calmette-Guérin (BCG) after surgery to eradicate residual disease and thus reduce the frequency of recurrences. recurrence and progression (Babjuk, 2017; Lindskrog, 2021).
Ludwig’s patented “index” has the potential to create a genetic signature in bladder cancer patients. This genetic signature provides a potential framework in bladder cancer clinical trials to optimize early diagnosis and clinical management with anticancer therapy.
The market for this advanced early detection system is also largely untapped, with little competition in the multi-billion dollar healthcare industry. Ludwig can use these cutting-edge technologies to help people live longer, healthier lives by providing sensitive testing methods that have the potential to detect genetic markers of inflammation in diseases, such as heart disease or cancer, before there are obvious symptoms. . Physicians can potentially monitor and modify a patient’s positive or negative response in the treatment process, potentially saving billions in healthcare costs for chronic conditions.
* Babjuk, M. et al. EAU guidelines on non-muscle invasive urothelial carcinoma of the bladder. EUR. Urol 71, 447-461 (2017). *Lindskrog, SV et al. 2021. Integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle invasive bladder cancer. Nature Communications. 12:2301.
About Ludwig Enterprises, Inc.: Advances in medical technology have given us state-of-the-art genetic tools unheard of even a generation ago. These genetic tools have the potential not only to detect diseases early, but also to personalize treatments that can improve patient outcomes and, in some cases, even prolong life. Ludwig is at the forefront of this new era of medicine with his proprietary mRNA genetics methodology that has the potential to detect genetic biomarkers for inflammatory diseases, including but not limited to heart disease, pre-eclampsia, and cancer. This early detection can allow doctors to take steps to diagnose and manage the disease before it progresses and causes serious health problems. Ludwig’s innovative testing approach is not only practical, but also has the potential to save the healthcare industry billions of dollars in costs. With a virtually untapped market and a multi-billion dollar healthcare industry, Ludwig is poised to significantly impact the way we think about disease and live longer, healthier lives. More information: http://www.ludwigent.com
Forward-looking statements in this release are made under the “safe harbor” provision of the Private Securities Litigation Reform Act of 1995. Ludwig Enterprises Inc.’s forward-looking statements are not a guarantee of future performance. This press release includes forward-looking statements about the future level of business of the parties. These statements are necessarily subject to risk and uncertainty. Actual results could differ materially from those projected in these forward-looking statements due to certain risk factors that could cause results to differ materially from estimated results. Management cautions that all statements regarding future results of operations are necessarily subject to risks, uncertainties and events that may be beyond the control of Ludwig Enterprises, Inc., and there can be no guarantee that such results will be achieved. Potential risks and uncertainties include, but are not limited to, the ability to acquire, properly price, retain and complete projects, and changes in products and competition.
FONT: Ludwig Enterprises, Inc.